Literature DB >> 24994841

Outcome after surgical or conservative management of cerebral cavernous malformations.

Fiona Moultrie1, Margaret A Horne1, Colin B Josephson1, Julie M Hall1, Carl E Counsell1, Jo J Bhattacharya1, Vakis Papanastassiou1, Robin J Sellar1, Charles P Warlow1, Gordon D Murray1, Rustam Al-Shahi Salman2.   

Abstract

OBJECTIVE: There have been few comparative studies of microsurgical excision vs conservative management of cerebral cavernous malformations (CCM) and none of them has reliably demonstrated a statistically and clinically significant difference.
METHODS: We conducted a prospective, population-based study to identify and independently validate definite CCM diagnoses first made in 1999-2003 in Scottish adult residents. We used multiple sources of prospective follow-up to assess adults' dependence and to identify and independently validate outcome events. We used univariate and multivariable survival analyses to test the influence of CCM excision on outcome, adjusted for prognostic factors and baseline imbalances.
RESULTS: Of 134 adults, 25 underwent CCM excision; these adults were younger (34 vs 43 years at diagnosis, p = 0.004) and more likely to present with symptomatic intracranial hemorrhage or focal neurologic deficit than adults managed conservatively (48% vs 26%; odds ratio 2.7, 95% confidence interval [CI] 1.1-6.5). During 5 years of follow-up, CCM excision was associated with a deterioration to an Oxford Handicap Scale score 2-6 sustained over at least 2 successive years (adjusted hazard ratio [HR] 2.2, 95% CI 1.1-4.3) and the occurrence of symptomatic intracranial hemorrhage or new focal neurologic deficit (adjusted HR 3.6, 95% CI 1.3-10.0).
CONCLUSIONS: CCM excision was associated with worse outcomes over 5 years compared to conservative management. Long-term follow-up will determine whether this difference is sustained over patients' lifetimes. Meanwhile, a randomized controlled trial appears justified. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that CCM excision worsens short-term disability scores and increases the risk of symptomatic intracranial hemorrhage and new focal neurologic deficits.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Year:  2014        PMID: 24994841      PMCID: PMC4141991          DOI: 10.1212/WNL.0000000000000684

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

Review 1.  Microsurgical treatment of supratentorial cavernous malformations.

Authors:  R G Ojemann; C S Ogilvy
Journal:  Neurosurg Clin N Am       Date:  1999-07       Impact factor: 2.509

2.  Prospective hemorrhage risk of intracerebral cavernous malformations.

Authors:  K D Flemming; M J Link; T J H Christianson; R D Brown
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

3.  When are randomised trials unnecessary? Picking signal from noise.

Authors:  Paul Glasziou; Iain Chalmers; Michael Rawlins; Peter McCulloch
Journal:  BMJ       Date:  2007-02-17

4.  Management of patients with cavernous angiomas presenting epileptic seizures.

Authors:  Sadami Noto; Masami Fujii; Tatsuo Akimura; Hirochika Imoto; Sadahiro Nomura; Koji Kajiwara; Shoichi Kato; Hirosuke Fujisawa; Michiyasu Suzuki
Journal:  Surg Neurol       Date:  2005-12

Review 5.  Comparative studies of the diagnosis and treatment of cerebral cavernous malformations in adults: systematic review.

Authors:  Michiel Poorthuis; Neshika Samarasekera; Krystle Kontoh; Ian Stuart; Buddug Cope; Neil Kitchen; Rustam Al-Shahi Salman
Journal:  Acta Neurochir (Wien)       Date:  2013-01-31       Impact factor: 2.216

6.  A single institution series of cavernomas of the brainstem.

Authors:  Girish Menon; C V Gopalakrishnan; B R M Rao; Suresh Nair; Jayanand Sudhir; Mridul Sharma
Journal:  J Clin Neurosci       Date:  2011-07-13       Impact factor: 1.961

7.  Scottish Intracranial Vascular Malformation Study (SIVMS): evaluation of methods, ICD-10 coding, and potential sources of bias in a prospective, population-based cohort.

Authors:  Rustam Al-Shahi; Jo J Bhattacharya; David G Currie; Vakis Papanastassiou; Vaughn Ritchie; Richard C Roberts; Robin J Sellar; Charles P Warlow
Journal:  Stroke       Date:  2003-04-17       Impact factor: 7.914

8.  Surgical versus conservative treatment in patients with cerebral cavernomas and non refractory epilepsy.

Authors:  Santiago Fernández; Júlia Miró; Mercé Falip; Alejandro Coello; Gerard Plans; Sara Castañer; Juan José Acebes
Journal:  Seizure       Date:  2012-09-23       Impact factor: 3.184

9.  Does conservative management for brain stem cavernomas have better long-term outcome?

Authors:  A Tarnaris; R P Fernandes; N D Kitchen
Journal:  Br J Neurosurg       Date:  2008-12       Impact factor: 1.596

10.  Risks of surgical management for cavernous malformations of the nervous system.

Authors:  S Amin-Hanjani; C S Ogilvy; R G Ojemann; R M Crowell
Journal:  Neurosurgery       Date:  1998-06       Impact factor: 4.654

View more
  15 in total

Review 1.  Cavernous angiomas: deconstructing a neurosurgical disease.

Authors:  Issam A Awad; Sean P Polster
Journal:  J Neurosurg       Date:  2019-07-01       Impact factor: 5.115

Review 2.  Cerebrovascular disorders associated with genetic lesions.

Authors:  Philipp Karschnia; Sayoko Nishimura; Angeliki Louvi
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

Review 3.  Rho kinase as a target for cerebral vascular disorders.

Authors:  Lisa M Bond; James R Sellers; Lisa McKerracher
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

4.  Surgical Approaches for Symptomatic Cerebral Cavernous Malformations of the Thalamus and Brainstem.

Authors:  Dale Ding; Robert M Starke; R Webster Crowley; Kenneth C Liu
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2017-03-31

5.  Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).

Authors:  Sean P Polster; Ying Cao; Timothy Carroll; Kelly Flemming; Romuald Girard; Daniel Hanley; Nicholas Hobson; Helen Kim; James Koenig; Janne Koskimäki; Karen Lane; Jennifer J Majersik; Nichol McBee; Leslie Morrison; Robert Shenkar; Agnieszka Stadnik; Richard E Thompson; Joseph Zabramski; Hussein A Zeineddine; Issam A Awad
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

6.  Difference of language cortex reorganization between cerebral arteriovenous malformations, cavernous malformations, and gliomas: a functional MRI study.

Authors:  Xiaofeng Deng; Long Xu; Yan Zhang; Bo Wang; Shuo Wang; Yuanli Zhao; Yong Cao; Dong Zhang; Rong Wang; Xun Ye; Jun Wu; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2015-11-13       Impact factor: 3.042

7.  Quality of life and mood assessment in conservatively treated cavernous malformation-related epilepsy.

Authors:  Laurèl Rauschenbach; Pauline Bartsch; Alejandro N Santos; Annika Lenkeit; Marvin Darkwah Oppong; Karsten H Wrede; Ramazan Jabbarli; Witold X Chmielewski; Börge Schmidt; Carlos M Quesada; Michael Forsting; Ulrich Sure; Philipp Dammann
Journal:  Brain Behav       Date:  2022-04-25       Impact factor: 3.405

8.  Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data.

Authors:  Margaret A Horne; Kelly D Flemming; I-Chang Su; Christian Stapf; Jin Pyeong Jeon; Da Li; Susanne S Maxwell; Philip White; Teresa J Christianson; Ronit Agid; Won-Sang Cho; Chang Wan Oh; Zhen Wu; Jun-Ting Zhang; Jeong Eun Kim; Karel Ter Brugge; Robert Willinsky; Robert D Brown; Gordon D Murray; Rustam Al-Shahi Salman
Journal:  Lancet Neurol       Date:  2015-12-02       Impact factor: 44.182

9.  Cerebral Cavernous Malformation: A Portuguese Family with a Novel CCM1 Mutation.

Authors:  João Pedro Marto; Inês Gil; Sofia Calado; Miguel Viana-Baptista
Journal:  Case Rep Neurol       Date:  2016-09-12

Review 10.  Surgery for cerebral cavernous malformations: a systematic review and meta-analysis.

Authors:  Lauren Harris; Michiel H F Poorthuis; Patrick Grover; Neil Kitchen; Rustam Al-Shahi Salman
Journal:  Neurosurg Rev       Date:  2021-06-30       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.